

CLAIMS:

1. (Canceled)
2. (Previously presented) The method according to claim 15, wherein said administering step includes administering the products in a method selected from the group consisting essentially of intravenously, intracoronary, and directly to the heart.
3. (Withdrawn) A therapeutic for treating heart failure, said therapeutic comprising stem cell products capable of delivery to the heart.
4. (Withdrawn) The therapeutic according to claim 3, wherein said stem cell products are selected from the group consisting essentially of VEGF, HGF, BDNF, NGF, BDNF, stat5, CNTF, NGF, bFGF, hypoxia-inducible factor-1-alpha, fibroblast growth factor, pharmacologic agents including immunosuppressants such as cyclosporin A, anti-inflammation agents such as dexamethasone, anti-angiogenic factors, acidic and basic fibroblast growth factors, vascular endothelial growth factor, hif-1, epidermal growth factor, transforming growth factor-alpha and beta, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor and insulin-like growth factor; growth factors; cell cycle inhibitors including CDK inhibitors; anti-restenosis agents, including p15, p16, p18, p19, p21, p27, p53, p57, Rb, nFkB, and E2F decoys, thymidine kinase ("TK"), anti-glial agents, and anti-mitotic factors.
5. (Withdrawn) The therapeutic according to claim 4, wherein said stem cell product is stat5.
- 6 - 7. (Canceled)
8. (Withdrawn) Stem cell products for use in treating heart failure.

9. (Withdrawn) The stem cell products according to claim 8, wherein said products are selected from the group consisting essentially of VEGF, HGF, BDNF, NGF, bFGF, and hypoxia-inducible factor-1-alpha.
10. (Withdrawn) The stem cell products according to claim 9, wherein said stem cell product is stat5.
11. (Withdrawn) A heart treated with stem cell products, said stem cell products restoring heart function.
12. (Withdrawn) A composition for enriching and regenerating damaged myocardium, said composition comprising stem cell products in a pharmaceutically acceptable carrier.
13. (Withdrawn) A composition for causing the expression of stem cell products.
14. (Withdrawn) A method of creating stem cells and stem cell products for use in treating heart failure and improving cardiac function by enriching medium containing stem cells by exposing the medium to hypoxia.
15. (Currently amended) A method of improving cardiac function by administering stem cell products consisting essentially of secretions from mesenchymal stem cells derived by: isolating the mesenchymal stem cells from harvested marrow; growing the mesenchymal stem cells without differentiation in medium; enriching the medium containing the mesencymal stem cells, and; separating the mesenchymal stem cells from a supernatant, the supernatant containing products consisting essentially of secretions from the mesenchymal stem cells; and improving cardiac function.

~~administering the products consisting essentially of the secretions from the stem cells.~~

16. (Currently amended) A method as set forth in claim 15, wherein said enriching step is further defined as exposing the mesenchymal stem cells and medium to hypoxia.